KOD: Kodiak Sciences Inc Market Capitalization to Book Value Ratio

Brandmark of Kodiak Pharma (KOD)

Kodiak Sciences Inc. (KOD) is developing biopharmaceutical agents for retinal therapy, leveraging a diversified portfolio of ophthalmology projects. Due to a unique long-acting molecular structure, the company will be able to establish its own pricing power following regulatory approval. This price action chart reflects a value of 102.98. However, previous clinical trial failures and the prolonged time-to-market are exerting significant pressure on the stock price.

Kodiak Sciences Inc. (KOD) - Market Capitalization to Book Value Ratio from 07/04/2022 to 10/31/2026

Analytical breakdowns and data insights for company Kodiak Sciences Inc (KOD)

- market value and analyst target forecast:
Price Chart Kodiak Sciences Inc.|KOD - Forecast Levels Chart
- market capitalization information:
Market Capitalization Kodiak Pharma|KOD - Value Adjusted for Debt and Cash
- balance sheet net asset value indicators:
Book Value per Share Kodiak Sciences|KOD - Book Capitalization|Market Value to Book Value Ratio kodiak.com|KOD - Aggregate Asset Value
- business debt structure and liquidity details:
Debt to Equity Kodiak Sciences Inc.|KOD - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Kodiak Pharma|KOD - Company Aggregate Debts|Debt to Book Value Kodiak Pharma|KOD - Company Long-Term Loans and Borrowings|Company Short-Term Debts Kodiak Sciences|Quick Liquidity Indicator kodiak.com
- earnings and valuation multiples indicators:
KOD - Company Net Income
Initial company analysis:Kodiak Sciences Inc., KOD
Manufactured product of Kodiak Sciences Inc

The financial potential of Kodiak Sciences Inc. (KOD) is based on the results of clinical trials for ophthalmological drugs, which prices in expectations for future insurance reimbursements into the stock value. This indicator compares the current market value of the business with its net assets, allowing for a determination of the premium paid for technological prospects or the risk of a price correction through the history of market valuation relative to book value.

Who Kodiak Sciences Inc. competes with

Alcon Inc. (ALC) - Market Value to Book Value Ratio|Market Capitalization to Net Assets BLCO (bausch.com)|GKOS (Glaukos) - Market Capitalization to Book Value Ratio|APLS: Market Value to Book Value|Market Capitalization to Book Value Ratio BLTE|Market Capitalization to Book Value Ratio Ocular Pharma (OCUL)|Market Value to Book Value Ratio Harrow, Inc. HROW|Market Value to Book Value VRDN|LENZ - Market Value to Book Value Ratio|oculis.com (OCS) - Market Cap to Net Assets Ratio|EYPT: Market Capitalization to Book Value Ratio|Aldeyra Therapeutics, Inc. (ALDX) - Market Capitalization to Book Value Ratio|Market Cap to Net Assets Ratio KALA|IRD: Market Value to Book Value|Market Capitalization to Book Value Ratio OKYO|ADVM - Market-to-Book Ratio|Outlook Pharma - Market Cap to Net Assets Ratio|Clearside Corp (CLSD) - Market-to-Book Ratio|NovaBay - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Kiora Pharmaceuticals|alimerasciences.com (ALIM) - Market Value to Book Value Ratio|EYEN - Market Capitalization to Book Value|Market Value to Book Value Ratio Guardion Health Sciences Inc.|Market Capitalization to Book Value Ratio Ocuphire Corporation|Market Value to Book Value Ratio Opthea Limited (OPT)